Long-Term Outcomes After Medical and Invasive Treatment in Patients With Hypertrophic Cardiomyopathy

JACC: Heart Failure

Volumn 2, Issue 6, 2014, Pages 630-636

  Vriesendorp, Pieter A ^a   Liebregts, Max ^b,c   Steggerda, Robbert C ^d   Schinkel, Arend F L ^a   Willems, Rik ^b   ten Cate, Folkert J ^a   van Cleemput, Johan ^b   ten Berg, Jurriën M ^c   Michels, Michelle ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d MARTINI HOSPITAL   (Netherlands)

Author keywords

Alcohol septal ablation; Hypertrophic cardiomyopathy; Left ventricular outflow tract obstruction; Suddencardiac death; Surgical myectomy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT;

ABLATION THERAPY; ADULT; ALCOHOL SEPTAL ABLATION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; FEMALE; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART TAMPONADE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INVASIVE PROCEDURE; KIDNEY FAILURE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MUSCLE RESECTION; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SELECTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; SUDDEN CARDIAC DEATH; SYSTOLIC DYSFUNCTION;

EID: 84951909635     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.06.012     Document Type: Article

References (31)

1. Maron M.S., Olivotto I., Zenovich A.G., et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006, 114:2232-2239.
2. Maron M.S., Olivotto I., Betocchi S., et al. Effect ofleft ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. NEngl J Med 2003, 348:295-303.
3. Elliott P.M., Gimeno J.R., Tome M.T., et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006, 27:1933-1941.
4. O'Mahony C., Jichi F., Pavlou M., et al. Anovel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur Heart J 2014, 35:2010-2020.
5. Maron B.J. Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 2007, 116:196-206.
6. Fifer M.A. Controversies in cardiovascular medicine. Most fully informed patients choose septal ablation over septal myectomy. Circulation 2007, 116:207-216.
7. Maron B.J., Yacoub M., Dearani J.A. Controversies in cardiovascular medicine. Benefits of surgery in obstructive hypertrophic cardiomyopathy: bring septal myectomy back for European patients. Eur Heart J 2011, 32:1055-1058.
8. Fifer M.A., Sigwart U. Controversies in cardiovascular medicine. Hypertrophic obstructive cardiomyopathy: alcohol septal ablation. Eur Heart J 2011, 32:1059-1064.
9. Kirklin J.W., Ellis F.H. Surgical relief of diffuse subvalvular aortic stenosis. Circulation 1961, 24:739-742.
10. Morrow A.G., Reitz B.A., Epstein S.E., et al. Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 1975, 52:88-102.
11. Ommen S.R., Maron B.J., Olivotto I., et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. JAm Coll Cardiol 2005, 46:470-476.
12. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995, 346:211-214.
13. Rigopoulos A.G., Seggewiss H. Adecade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J 2011, 75:28-37.
14. Boltwood C.M., Chien W., Ports T. Ventricular tachycardia complicating alcohol septal ablation. NEngl J Med 2004, 351:1914-1915.
15. Kuhn H., Lawrenz T., Lieder F., et al. Survival after transcoronary ablation of septal hypertrophyin hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol 2008, 97:234-243.
16. Sorajja P., Valeti U., Nishimura R.A., et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2008, 118:131-139.
17. ten Cate F.J., Soliman O.I., Michels M., et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail 2010, 3:362-369.
18. Olivotto I., Ommen S.R., Maron M.S., Cecchi F., Maron B.J. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial?. JAm Coll Cardiol 2007, 50:831-834.
19. Agarwal S., Tuzcu E.M., Desai M.Y., et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. JAm Coll Cardiol 2010, 55:823-834.
20. Leonardi R.A., Kransdorf E.P., Simel D.L., Wang A. Meta-analyses of septal reduction therapies forobstructive hypertrophic cardiomyopathy: comparative rates of overall mortality and sudden cardiac death after treatment. Circ Cardiovasc Interv 2010, 3:97-104.
21. Ball W., Ivanov J., Rakowski H., et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. JAm Coll Cardiol 2011, 58:2313-2321.
22. Nagueh S.F., Groves B.M., Schwartz L., et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. A multicenter North American registry. JAm Coll Cardiol 2011, 58:2322-2328.
23. Jensen M.K., Prinz C., Horstkotte D., et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart 2013, 99:1012-1017.
24. Sorajja P., Ommen S.R., Holmes D.R., et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2012, 126:2374-2380.
25. Maron B.J., McKenna W.J., Danielson G.K., et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy-a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. European Heart Journal 2003, 24:1965-1991.
26. Gersh B.J., Maron B.J., Bonow R.O., et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2011, 58:2703-2738.
27. Maat L.P., Slager C.J., van Herwerden L.A., et al. Spark erosion myectomy in hypertrophic obstructive cardiomyopathy. Ann Thorac Surg 1994, 58:536-540.
28. van der Lee C., ten Cate F.J., Geleijnse M.L., et al. Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets. Circulation 2005, 112:482-488.
29. van der Lee C., Scholzel B., ten Berg J.M., et al. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. Am J Cardiol 2008, 101:1315-1320.
30. Nishimura R.A., Ommen S.R. Septal reductiontherapy for obstructive hypertrophic cardiomyopathy and sudden death: what statistics cannot tell you. Circ Cardiovasc Interv 2010, 3:91-93.
31. McLeod C.J., Ommen S.R., Ackerman M.J., et al. Surgical septal myectomy decreases the risk forappropriate implantable cardioverter defibrillator discharge in obstructive hypertrophiccardiomyopathy. Eur Heart J 2007, 28:2583-2588.